Overview

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Status:
Completed

Trial end date:
2019-05-21

Target enrollment:

Participant gender:

Summary

The main objectives of this study were to estimate the absolute bioavailability of ravulizumab/rHuPH20 subcutaneous (SC) and to assess the safety and tolerability of ravulizumab/rHuPH20 SC.

Phase:

Phase 1

Details

Lead Sponsor:

Alexion Pharmaceuticals

Treatments:

Ravulizumab